# Chloroform associated with bone mineral density and bone mineral content in adults: a population-based cross-sectional research.

- Lin Li<sup>1</sup>¶, XK Liu<sup>2</sup>¶, Xia Zhang<sup>3</sup>¶, Yan Zhang<sup>3</sup>¶, Qing Li<sup>3</sup>¶, HF Geng<sup>2</sup>, Li Shi<sup>2</sup>, Ben 1
- Wang<sup>2</sup>, QQ Qiu<sup>2</sup>, TP Yu<sup>2</sup>, YQ Sang<sup>2</sup>, LY Wang<sup>2</sup>, Wei Xu<sup>2\*</sup>, Jun Liang<sup>1, 2\*</sup> 2
- <sup>1</sup>Graduate School of Bengbu Medical College, Bengbu, Anhui, China. 3
- <sup>2</sup>Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Institute of Medical 4
- Sciences, Xuzhou Clinical School of Nanjing Medical University, Affiliated Hospital 5
- of Medical School of Southeast University, Jiangsu, China. 6
- <sup>3</sup>Xuzhou Medical University, Xuzhou, Jiangsu, China. 7
- First-author: 8
- Lin Li, email: 1621561732@gg.com 9
- **Co-authors:** 10
- XK Liu, email: liuxuekui314@126.com 11
- Xia Zhang, email: garnele99@163.com 12
- Yan Zhang, email: zhangyan202103@126.com 13
- 14 Qing Li, email: 769798497@qq.com
- HF Geng, email: genghoufa@njmu.edu.cn 15
- Li Shi, email: shili2006 2009@126.com 16
- Ben Wang, email: wangben1210@126.com 17
- QQ Qiu, email: qqq18796249070@163.com 18
- TP Yu, email: yutianpei1188@163.com 19
- YQ Sang, email: sangyiquan86@163.com 20
- LY Wang, email: 786773733@gg.com 21
- These authors contributed equally to this work. 22
- \* Correspondence: 23

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- Jun Liang, email: mwlj521@njmu.edu.cn 24
- Wei Xu, email: weixu159357@njmu.edu.cn 25

**Abstract** 

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

**Background:** According to a recent cross-sectional study, reduced Bone Mineral Density (BMD) in U.S. adults is associated with co-exposure to several Volatile Organic Compounds (VOCs), and contact with VOCs increases the risk of developing osteoporosis. However, the relationship between chloroform (an essential VOC component) and BMD remains unclear. Consequently, we aimed to explore the relationship between chloroform alone and Bone Mineral Density or Bone Mineral Content (BMD or BMC). **Methods:** Herein, 2.553 individuals aged 18 and above from the National Health and Nutrition Examination Surveys (NHANES) in 2009-2010, 2013-2014, and 2017-2020, were included. We employed two independent t-tests and multi-linear regression models to statistically assess the relationship between chloroform exposure and BMD/BMC in the spine and femoral area. **Results:** A "V"-shaped correlation between chloroform exposure and BMD/BMC was observed in the unadjusted model, particularly in the Ward's triangle and femoral neck as a whole. A negative correlation was specifically observed for the Ward's triangle BMD/BMC and L4 BMD/BMC. On the other hand, in the adjusted model, a dominantly negative correlation between the L4 BMC and chloroform exposure was observed over a range of exposure levels. The subgroup analysis revealed a negative correlation between chloroform concentrations and BMC in the femur and spine, especially in women and the 65-80 age population.

47 **Conclusion:** Our study revealed a "V" shaped correlation between chloroform and

BMD/BMC of the femur and spine in U.S. adults. This finding highlights the fact that

prolonged exposure to chloroform may increase the risk of developing osteoporosis.

### **Introduction:**

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Osteoporosis is a frequent bone disease characterized by reduced bone volume, microstructural degeneration, and fragility fractures [1]. Fragility fractures, particularly in the most vulnerable areas, including the vertebrae, hip, and forearm, are one of the severe complications of osteoporosis. According to reports [2,3], fragility fractures can cause emotional distress, reduced quality of life, and an increased socioeconomic burden. Approximately 79,000 people in the United Kingdom suffer hip fractures annually, with the cost in 2010 estimated at £3.5 billion and expected to rise to £5.5 billion each year by 2025, implying that osteoporosis will be a significant challenge in the future and its burden on the medical community must be removed [4]. According to osteoporosis research, enhancing Bone Mineral Density (BMD) is closely linked to decreasing the risk of vertebral and non-vertebral fractures [5]. Many factors, including aging, femininity, estrogen metabolism disturbances, and physical inactivity, are critical in lowering BMD and have been implicated in the pathogenesis of osteoporosis [6,7].People are frequently exposed to Volatile Organic Compounds (VOCs) such as chloroform, bromoform, dibromochloromethane, and dichlorobromomethane. The

increased contact is due to the widespread use of disinfectants, as these VOCs are

Compared to normal mice, the U.S. National Toxicology Program noted an increased incidence of sternal dysplasia in bromoform-exposed mice [11]. Other studies discovered a connection between VOC exposure and bone-healing-related chemokines, with a downregulated osteoblast chemokine CXCL12 expression after exposure to benzene or its derivatives, and that CCL2 (a chemokine essential for osteoclast formation) production was induced by chlorobenzene exposure [12, 13, 14]. These findings imply that VOCs could impact BMD levels by affecting osteoblast activity. Additionally, individual and combined VOC exposure was found to be associated with lower BMD in U.S. adults, and Alkaline Phosphatase (ALP), Body Mass Index (BMI), Fasting Insulin (F.I.), and High-Density Lipoprotein (HDL) were shown to be intermediaries in VOC and BMD co-exposure [15]. Chloroform, a significant member of VOCs, is strongly absorbed through the pulmonary, oral, and dermal pathways and is linked with several acute and chronic illnesses, including neurological, respiratory, hepatic, and renal dysfunctions, reproductive abnormalities, and digestive or urinary malignancies [16, 17]. However, the connection between blood chloroform and BMD/BMC was rarely investigated alone in past studies. This research aimed to explore the relationship between blood chloroform and BMD/BMC using data from the National Health and Nutrition Examination Survey (NHANES). We, therefore, obtained femur BMD/BMC and spine BMD/BMC datasets

### Materials and methods

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

published in 2009-2010, 2013-2014, and 2017-2020 from NHANES.

### Study design and participants

Herein, data from the NHANES, a cross-sectional survey of more than 5,000 respondents conducted yearly by the Center for Disease Control and Prevention's (CDC) Center for Health Statistics, was used. We specifically used NHANES data from 2009-2010, 2013-2014, and 2017-2020. We selected 22,333 adults (of whom 6,227 had blood chloroform data) from 36,272 available subjects. Subsequently, 2637 individuals with femur and spine Dual-Energy X-ray Absorptiometry (DEXA) data were selected. After excluding patients with a history of osteoporosis treatment, 2553 subjects aged ≥18 years were included in the final statistical analysis. **Fig1** depicts the flowchart for participant exclusion. (**Fig1:** Flowchart for Screening Research Subjects)

#### Variables

In this study, we used blood chloroform concentration as the exposure variable. Chloroform concentration in the blood was analyzed using Capillary Gas Chromatography (G.C.) and Mass Spectrometry (M.S.) with Selected Ion Monitoring (SIM) detection and isotope dilution. The chloroform detection limits ranged from 0.00148 to 0.602 ng/ml, and for lower LLOD (Lower Limit of Detection) values, an interpolated LLOD value divided by the square root of 2 was used. The dependent variables were the femoral and spinal Bone Mineral Density (BMD) and Bone Mineral Content (BMC). In Shepherd's laboratory, Dual-Energy X-ray Absorptiometry (DXA) was used to measure the spine and femur BMC, whereas the Hologic software APEX v4.0 (Hologic) sector beam densitometry was used to scan and calculate the spine and femur BMC and BMD. All variables included as covariates in the study are listed below:

Gender (male, female), Race/ethnicity (Mexican-American, Non-Hispanic white, Non-Hispanic black, other Hispanic, other race), Household Poverty-Income Ratio (PIR by poverty line: values 0 to 0.99 indicate below poverty, ≥1.00 indicate poverty or above poverty)[18], Excessive alcohol consumption (>1 drink /day for women or >2 drinks /day for men (in the past 12 months)), Hypertension (blood pressure ≥140/90 mmHg or taking anti-hypertensive medication), Diabetes mellitus (self-reported diabetes history, Fasting Blood Glucose (FPG) level ≥7.0 mmol/L, HbA1c ≥6.5% or taking anti-diabetic medication), Arthritis, Cardiovascular disease (self-reported congestive heart failure, coronary artery disease, heart attack or stroke history), Thyroid problems (self-reported hyperthyroidism, hypothyroidism, thyroiditis), COPD(Chronic Obstructive Pulmonary Disease), Smoking (self-described as having smoked ≥100 cigarettes in a lifetime), History of osteoporosis treatment and osteopenia (Bone Mineral Density (BMD) Tscore  $\leq$  -2.5 in lumbar spine or femoral neck) [19]. Age, body weight, abdominal circumference, and BMI were all continuous covariates in our analysis. The blood chloroform, BMD, BMC, and covariance data were obtained from the NHANES website.

# Statistical analysis

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

Statistical analyses were conducted using R software (version 3.6.1), IBM SPSS version 25(IBM, Armonk, New York, USA), and GraphPad Prism9. The mean and Standard Deviation (S.D.) values were used for variables with continuous features, whereas categorical variable represented frequency. The Spearman correlation test was used to assess differences between the classification variables in the exposure

group. The Kruskal-Wallis test or one-way ANOVA was used to examine differences in continuous variables between groups. Blood chloroform levels were grouped into tertiles (tertile 1: <33%, tertile 2: 33-66%, tertile 3: >66%) and univariate and multivariate linear regression models were tested to analyze the relationship between the different blood chloroform categories. We adjusted the confounding variables in the multi-linear regression model to investigate the correlation between blood chloroform levels and BMD/BMC (femoral and spine). These included Model 1 (the unprecedented model), Model 2 (for gender, age, race, and BMI adjustment), and Model 3 (for gender, age, race, BMI, osteoporosis, COPD, and thyroid problems adjustments, and further adjustment for arthritis, smoking and excessive drinking). Regression analysis results were expressed as β (beta) coefficients, 95% confidence intervals, and statistically significant P values (P values<0.05).

# **Results**

# **Subjects characteristics**

This study had 2553 participants (1288 women and 1265 men). Based on the femoral and spinal DEXA data, the average age of the participants and the average chloroform levels in their whole blood was 48.83 years and  $0.0171 \pm 0.0182$  ng/mL (ranging from 0.0021 to 0.1790 ng/mL), respectively. The weighted characteristics of these participants based on the third-class classification are shown in **TableS1**. According to the femoral and spine DEXA data, differences among groups in baseline variables such as age, race, height, BMI, waist circumference, hypertension, arthritis, thyroid illnesses, and smoking were statistically significant (P<0.05).

#### Connection between chloroform and BMD

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

Tables1-2 and S2 illustrate the results. Blood chloroform concentration by tertile had a statistically significant relationship with total femoral BMD (P < 0.05); femoral neck BMD (P < 0.01); rotor BMD (P < 0.05); inter-rotor BMD (P < 0.05); Ward's triangle BMD (P < 0.01); and L4 BMD (P < 0.01). The multiple linear regression models and weighted univariate analyses are detailed in Tables1-2. All regressions were conducted before adjusting for some of the covariates (model 1), except for total spine BMD (β -0.0020; 95% CI -0.0051, 0.0011), L1 BMD (β 0.0004; 95% CI -0.0030, 0.0039), L2 BMD (β - 0.0024; 95% CI -0.0057, 0.0009), and L3 BMD (β -0.0016; 95% CI -0.0048, 0.0016). A statistically significant correlation existed between increased blood chloroform concentration and total femoral BMD, femoral neck BMD, rotor BMD, inter-rotor BMD, Ward's triangle BMD, and L4 BMD (P<0.05). The L4 BMD was negatively correlated with blood chloroform levels after adjusting for some covariates (model 2). After adjusting for more relevant covariates simultaneously (model 3), L4 BMD decreased with rising blood chloroform levels, but not at other sites.

		Model1	Model2	Model3
		β(95%CI) value	β(95%CI) P value	β(95%CI) P value
	Chloroform (ng/mL)			
Total femur BMD(g/cm2)*	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2: 0.00875-0.01690ng/ml	0.0014(-0.0054,0.0083)0.681	0.0043(-0.0012,0.0098)0.123	0.0047(-0.0007,0.0102)0.090
	Q3: 0.01700-0.17900ng/ml	-0.0082(-0.0150,-0.0014)0.019	Reference	-0.0029(-0.0084,0.0026)0.308
	Chloroform (ng/mL)			
Total femur BMC(g)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2 : 0.00875-0.01690ng/ml	0.0034(-0.0075,0.0144)0.542	0.0021(-0.0052,0.0094)0.574	0.0024(-0.0049,0.0097)0.520
	O3: 0.01700-0.17900ng/ml	-0.0142(-0.0252,-0.0033)0.011	-0.0060(-0.0133,0.0014)0.112	-0.0064(-0.0138,0.0009)0.087
	Chloroform (ng/mL)	,,		
	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
Femoral neck BMD(g/cm2)	Q2: 0.00875-0.01690ng/ml	-0.0071(-0.0148,0.0005)0.070	-0.0005(-0.0066,0.0056)0.876	-0.0001(-0.0062,0.0060)0.983
	Q3 : 0.01700-0.17900ng/ml	-0.0089(-0.0166,-0.0012)0.024	-0.0004(-0.0066,0.0057)0.889	-0.0011(-0.0073,0.0050)0.714
	Chloroform (ng/mL)			
- 1 1 DMG()	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
Femoral neck BMC(g)	Q2 : 0.00875-0.01690ng/ml	-0.0055(-0.0147,0.0037)0.238	-0.0009(-0.0076,0.0058)0.789	-0.0006(-0.0073,0.0061)0.871
	Q3 : 0.01700-0.17900ng/ml	-0.0142(-0.0233,-0.0051)0.002	-0.0040(-0.0107,0.0028)0.249	-0.0046(-0.0113,0.0021)0.182
	Chloroform (ng/mL)			
Frochanter BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
Frochanter BMD(g/cm2)	Q2: 0.00875-0.01690ng/ml	0.0031(-0.0043,0.0106)0.411	0.0055(-0.0008,0.0119)0.089	0.0060(-0.0004,0.0123)0.065
	Q3 : 0.01700-0.17900ng/ml	-0.0090(-0.0164,-0.0015)0.018	-0.0037(-0.0101,0.0026)0.250	-0.0045(-0.0109,0.0019)0.164
	Chloroform (ng/mL)			
Trochanter BMC (g)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
Frochanter BIVIC (g)	Q2 : 0.00875-0.01690ng/ml	0.0070(-0.0050,0.0189)0.253	0.0037(-0.0051,0.0124)0.409	0.0040(-0.0047,0.0127)0.371
	Q3: 0.01700-0.17900ng/ml	-0.0116(-0.0234,0.0005)0.059	-0.0053(-0.0140,0.0035)0.239	-0.0057(-0.0145,0.0030)0.198
	Chloroform (ng/mL)			
intertrochanter BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
memochaniei BWD(g/cm2)	Q2: 0.00875-0.01690ng/ml	0.0032(-0.0035,0.0100)0.349	0.0054(-0.0001,0.0110)0.055	0.0058(0.0003,0.0114)0.039
	Q3 : 0.01700-0.17900ng/ml	-0.0070(-0.0138,-0.0002)0.043	-0.0016(-0.0072,0.0040)0.566	-0.0021(-0.0077,0.0034)0.445
	Chloroform (ng/mL)			
Intertrochanter BMC (g)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
intertrochanter BMC (g)	Q2: 0.00875-0.01690ng/ml	0.0038(-0.0078,0.0154)0.521	0.0021(-0.0057,0.0099)0.596	0.0024(-0.0054,0.0102)0.547
	Q3: 0.01700-0.17900ng/ml	-0.0151(-0.0267,-0.0036)0.010	-0.0064(-0.0143,0.0014)0.107	-0.0068(-0.0147,0.0010)0.086
	Chloroform (ng/mL)			
Wards triangle BMD(g/cm2)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
wards triangle DMD(g/elliz)	Q2: 0.00875-0.01690ng/ml	-0.0116(-0.0241,0.0009)0.069	0.0059(-0.0037,0.0155)0.228	0.0068(-0.0027,0.0163)0.162
	Q3: 0.01700-0.17900ng/ml	-0.0184(-0.0301,-0.0059)0.004	-0.0002(-0.0098,0.0094)0.962	-0.0017(-0.0113,0.0078)0.725
	Chloroform (ng/mL)			
Wards triangle BMC (g)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
rrando trialigio Divic (g)	Q2: 0.00875-0.01690ng/ml	-0.0117(-0.0253,0.0019)0.091	0.0073(-0.0032,0.0179)0.172	0.0083(-0.0022,0.0188)0.120
	Q3 : 0.01700-0.17900ng/ml	-0.0209(-0.0345,-0.0074)0.002	-0.0023(-0.0129,0.0083)0.666	-0.0040(-0.0145,0.0065)0.457

Model 1:no covariates were adjusted; Model 2:sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic White, non-Hispanic White, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted.

\*Logarithmic conversion of all BMD/BMC data.

172

173

174

175

176

		Model1	Model2	Model3
		β(95%CI) value	β(95%CI) P value	β(95%CI) P value
	Chloroform (ng/mL)			
Total spine BMD(g/cm2)*	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2: 0.00875-0.01690ng/ml	0.0018(-0.0045,0.0082)0.572	0.0023(-0.0037,0.0082)0.456	0.00241(-0.0035,0.0083)0.424
	Q3: 0.01700-0.17900ng/ml	-0.0054(-0.0118,0.0009)0.093	-0.0049(-0.0109,0.0010)0.106	-0.0050(-0.0109,0.0010)0.100
	Chloroform (ng/mL)			
Total spine BMC (g)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
	Q2: 0.00875-0.01690ng/ml	0.0036(-0.0062,0.0135)0.471	0.0027(-0.0059,0.0113)0.535	0.0029(-0.0057,0.0114)0.510
	Q3 : 0.01700-0.17900ng/ml	-0.0110(-0.0208,-0.0012)0.028	-0.0080(-0.0166,0.0006)0.068	-0.0080(-0.0165,0.0006)0.068
	Chloroform (ng/mL)			
.1 BMD(g/cm2)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
.i BMD(geniz)	Q2: 0.00875-0.01690ng/ml	0.0039(-0.0030,0.0108)0.266	0.0040(-0.0023,0.0103)0.211	0.0042(-0.0021,0.0104)0.194
	Q3: 0.01700-0.17900ng/ml	-0.0014(-0.0083,0.0055)0.695	-0.0002(-0.0066,0.0061)0.941	-0.0002(-0.0065,0.0061)0.951
	Chloroform (ng/mL)			
LBMC (a)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
.1 BMC (g)	Q2: 0.00875-0.01690ng/ml	0.0083(-0.0026,0.0191)0.136	0.0053(-0.0038,0.0144)0.251	0.0054(-0.0036,0.0144)0.241
	Q3: 0.01700-0.17900ng/ml	-0.0030(-0.0138,0.0079)0.592	-0.0001(-0.0092,0.0090)0.986	0.0002(-0.0089,0.0093)0.970
	Chloroform (ng/mL)			
2 DMD(-(2)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
2 BMD(g/cm2)	Q2: 0.00875-0.01690ng/ml	0.0007(-0.0060,0.0073)0.839	0.0020(-0.0042,0.0081)0.533	0.0021(-0.0040,0.0082)0.498
	Q3 : 0.01700-0.17900ng/ml	-0.0062(-0.0128,0.0004)0.066	-0.0045(-0.0107,0.0017)0.155	-0.0046(-0.0107,0.0016)0.147
	Chloroform (ng/mL)			
2 BMC (g)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
2 BMC (g)	Q2 : 0.00875-0.01690ng/ml	0.0054(-0.0048,0.0157)0.297	0.0045(-0.0042,0.0133)0.310	0.0046(-0.0041,0.0133)0.297
	Q3: 0.01700-0.17900ng/ml	-0.0118(-0.0220,-0.0016)0.023	-0.0078(-0.0166,0.0010)0.082	-0.0076(-0.0164,0.0011)0.086
	Chloroform (ng/mL)			
3 BMD(g/cm2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
3 BMD(g/cm2)	Q2: 0.00875-0.01690ng/ml	0.0012(-0.0053,0.0077)0.719	0.0017(-0.0045,0.0079)0.595	0.0018(-0.0043,0.0079)0.566
	Q3 : 0.01700-0.17900ng/ml	-0.0050(-0.0115,0.0015)0.130	-0.005(-0.0113,0.0011)0.105	-0.0052(-0.0113,0.0010)0.101
	Chloroform (ng/mL)			
2.01/2. ( )	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
.3 BMC (g)	Q2 : 0.00875-0.01690ng/ml	0.005517(-0.0042,0.0153)0.267	0.0048(-0.0039,0.0135)0.281	0.0049(-0.0037, 0.0136) 0.263
	Q3: 0.01700-0.17900ng/ml	-0.0116(-0.0213,-0.0019)0.020	-0.0091(-0.0178,-0.0004)0.040	-0.0092(-0.0178,-0.0005)0.038
	Chloroform (ng/mL)			
4 DMD(-(2)	Q1 : 0.00210-0.00874ng/ml	Reference	Reference	Reference
4 BMD(g/cm2)	Q2: 0.00875-0.01690ng/ml	0.0023(-0.0043,0.0088)0.494	0.0020(-0.0042,0.0083)0.527	0.0022(-0.0040,0.0084)0.489
	Q3: 0.01700-0.17900ng/ml	-0.0073(-0.0138,-0.0008)0.028	-0.0078(-0.0140,-0.0015)0.015	-0.0079(-0.0141,-0.0017)0.013
	Chloroform (ng/mL)			
4 DMC (-)	Q1: 0.00210-0.00874ng/ml	Reference	Reference	Reference
A BMC (g)	Q2: 0.00875-0.01690ng/ml	0.0015(-0.0083,0.0114)0.758	0.0004(-0.0085,0.0093)0.926	0.0006(-0.0082,0.0095)0.889
	Q3 · 0.01700-0.17900ng/ml	-0.0145(-0.0243,-0.0047)0.004	-0.0128(-0.0217,-0.0039)0.005	-0.0129(-0.0218,-0.0041)0.004

Model 1:no covariates were adjusted; Model 2:sex, age, race/ethnicity (Mexican American, other Hispanic Nhite, non-Hispanic Black, other races), BMI were adjusted; Model 3: sex, age, race/ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, other races), BMI, smoking, alcohol consumption, arthritis, COPD, history of osteoporosis, thyroid problems were adjusted.

\*Logarithmic conversion of all BMD/BMC data.

### Connection between chloroform and BMC

Detailed results are presented in Tables1-2 and S2. Weighted univariate and multiple 177

linear regression analyses are illustrated in Tables 1-2. In model 1, blood chloroform levels were categorized by tertile, except for rotor BMC ( $\beta$  -0.0023; 95% CI -0.0066, 0.0021), and L1 BMC ( $\beta$  -0.0004; 95% CI -0.0058, 0.0049). There was a negative correlation between increased blood chloroform concentrations and BMC at several sites, including total femoral BMC, femoral neck BMC, Intertrochanter BMC, Ward's triangle BMC, total spine BMC, L2 BMC, L3 BMC, and L4 BMC. Additionally, increased blood chloroform concentrations in the femur and spine were negatively correlated with BMC (P < 0.05). The L3 BMC and L4 BMC were negatively correlated with blood chloroform levels after adjusting for some covariates (model 2). Finally, in model 3, L3 BMC and L4 BMC decreased with increasing blood chloroform concentration.

# Subgroup analysis

Tables3-5. According to the Multiple regression analysis in the femoral area, the femoral neck BMC blood chloroform level decreased in the male gender (β -0.0059; 95 % CI -0.0115, -0.0002; P <0.05). According to the analysis by race as a subgroup, the femoral neck BMD/BMC in Non-Hispanic White and other Race-Including Multi-Racial subjects exhibited a negative correlation with blood chloroform concentration (P<0.05). In contrast, no meaningful correlation between blood chloroform and BMD or BMC was observed in Mexican-American, Non-Hispanic Black, and Other Hispanic subjects. A negative correlation between blood chloroform and femoral neck BMD/BMC was revealed by the results stratified by age but only in the 65-80 years-

perpetuity.

It is made available under a CC-BY 4.0 International license.

old participants (β -0.0100; 95% CI -0.0186, -0.0014; P<0.05); (β -0.0144; 95% CI -

201 0.0234, -0.0054; P<0.05).

200

202

203

204

205

206

207

208

Table3 Association of blood chloroform with femur neck BMD/BMC, stratified by sex, race/ethnicity and age.

fe	emur neckBMD (g/cm2)	β(95%CI) value	femur neck (g)	β(95%CI) value
Subgroup analysis stratified by gender				
male	-0.0020(-0.0073,0.0	0033)0.454	-0.0045(-0.	0100,0.0011)0.114
female	-0.0046(-0.0100,0.0	0008)0.094	-0.0059(-0.0	0115,-0.0002)0.041
Subgroup analysis stratified by race/ethi	nicity			
Mexican American	-0.0020(-0.0098,0.0	0058)0.617	-0.0041(-0.	0139,0.0058)0.416
Other Hispanic	-0.0052(-0.0163,0.0	0060)0.361	-0.0079(-0.	0215,0.0057)0.253
Non-Hispanic White	-0.0075(-0.0135,-0.	0015)0.015	-0.0086(-0.0	0158,-0.0015)0.018
Non-Hispanic Black	-0.0086(-0.0178,0.0	006)0.0664	-0.0104(-0.	0211,0.0003)0.056
Other Race—Including Multi-Racial	-0.0119(-0.0242,0.0	0003)0.056	-0.0171(-0.0	0324,-0.0018)0.028
Subgroup analysis stratified by age				
18-45	0.0034(-0.0010,0.0	0078)0.126	0.0018(-0.0	0031,0.0066)0.478
45-65	0.0016(-0.0032,0.0	0064)0.517	-0.0006(-0.	0058,0.0047)0.832
65-80	-0.0100(-0.0186 -0	0014)0 022	-0.0144(-0.0	234 -0 0054)0 002

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

Table4 Association of blood chloroform with wards triangle BMD/BMC, stratified by sex, race/ethnicity and age

	Wards triangle BMD (g/cm2)	β(95%CI) value	Wards triangleBMC (g)	β(95%CI) value
Subgroup analysis stratified by gender				
male	-0.0020(-0.0110,0.	0069)0.658	-0.0023(-0.0118,	0.0072)0.634
female	-0.0118(-0.0204,-0	.0032)0.007	-0.0144(-0.0239,-	0.0049)0.003
Subgroup analysis stratified by race/eth	nnicity			
Mexican American	-0.0024(-0.0148,0.	0100)0.703	-0.0036(-0.0172,	0.0100)0.605
Other Hispanic	-0.0068(-0.0244,0.	0109)0.451	-0.0090(-0.0281,	0.0102)0.358
Non-Hispanic White	-0.0124(-0.0224,-0	.0024)0.015	-0.0136(-0.0244,-	0.0027)0.015
Non-Hispanic Black	-0.0133(-0.0286,0.	0021)0.091	-0.0153(-0.0318,	0.0012)0.070
Other Race—Including Multi-Racial	-0.0103(-0.0293,0.	0087)0.289	-0.0118(-0.0324,0	0.0089)0.2639
Subgroup analysis stratified by age				
18-45	0.0037(-0.0025,0.	0099)0.241	0.0018(-0.0052,0	0.0088)0.616
45-65	0.0052(-0.0023,0.	0128)0.175	0.0049(-0.0034,0	0.0131)0.251
65-80	-0.0065(-0.0211,0.	0081)0.381	-0.0060(-0.0216,	0.0095)0.447

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

Table5 Association of blood chloroform with L4 BMD/BMC, stratified by sex, race/ethnicity and age.

	L4BMD (g/cm2)	β(95%CI) value	L4BMC (g)	β(95%CI) value
Subgroup analysis stratified by gender				
male	-0.0012(-0.00	57,0.0033)0.600	-0.0034(-0.00	98,0.0030)0.297
female	-0.0044(-0.00	90,0.0002)0.060	-0.009(-0.014	19,-0.0022)0.009
Subgroup analysis stratified by race/ethni	city			
Mexican American	-0.0055(-0.01	25,0.0015)0.124	-0.0107(-0.02	217,0.0002)0.054
Other Hispanic	-0.0028(-0.01	24,0.0067)0.560	-0.0058(-0.02	204,0.0088)0.437
Non-Hispanic White	-0.0044(-0.00	93,0.0005)0.082	-0.0078(-0.01	52,-0.0005)0.037
Non-Hispanic Black	-0.0066(-0.0142,0.0011)0.095		-0.0109(-0.0223,0.0004)0.059	
Other Race—Including Multi-Racial	-0.0057(-0.01	68,0.0054)0.313	-0.0113(-0.02	286,0.0059)0.196
Subgroup analysis stratified by age				
18-45	0.0001(-0.00)	37,0.0039)0.957	-0.0014(-0.00	71,0.0043)0.625
45-65	-0.0037(-0.00	88,0.0014)0.156	-0.0073(-0.01	45,-0.0001)0.047
65-80	-0.0072(-0.01	62,0.0018)0.119	-0.0154(-0.02	82,-0.0026)0.018

Adjustments were made for age, sex, race/ethnicity (Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, other race), BMI, alcohol consumption, osteoporosis, COPD, thyroid problems, arthritis, and smoking. In subgroup analyses stratified by gender or race/ethnicity, the model was not adjusted for the stratification variables themselves.

Results of the multiple regression analysis of Ward's triangle region revealed that stratified by gender, female Ward's triangle BMD decreased while chloroform levels

increased and that female Ward's triangle BMC was negatively correlated with chloroform. According to the results stratified by race, blood chloroform concentration was negatively correlated with BMD/BMC except for Hispanic white subjects (β -0.0124; 95%CI -0.0224, -0.0024; P<0.05); (β -0.0136; 95% CI -0.0244, -0.0027; P<0.05). Additionally, although BMC was not statistically significant, chloroform concentrations were correlated with BMD in Mexican-American, Other Hispanic, Non-Hispanic Black and Other Race-Including Multi-Racial participants. The results stratified by age revealed no statistically significant association between chloroform concentrations and BMD and BMC at all femoral sites in all age groups. Female L4 BMC decreased with increasing blood chloroform in the spinal region following stratification by sex (β -0.009; 95% CI -0.0149, -0.0022; P<0.01). When stratified by race, we discovered a significant correlation between Non-Hispanic White BMC and blood chloroform (β -0.0078; 95% CI -0.0152, -0.0005; P<0.05). Additionally, there was a significant negative correlation between BMC and chloroform in the 45-65 and 65-80 age groups when age was used as a stratification factor (β -0.0073; 95% CI -0.0145, -0.0001; P<0.05); (β -0.0154; 95% CI -0.0282, -0.0026; P< 0.05).

# **Discussion**

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

Osteoporosis is a degenerative bone disease that increases the risk of fracture [20]. With the aging population, osteoporosis is becoming a major public health concern worldwide [21,22]. The current era of rapid global economic development characterized by various industrial processes, including increased production of

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

automobiles, tobacco, cleaning products, building materials, and other household products, has made VOCs more common in the human environment [23,24,25,26,27]. Several studies have demonstrated that some VOCs, such as Perfluoro and Polyfluoroalkyl Substances (PFAS), Urinary Polycyclic Aromatic Hydrocarbons (UPAHs), trichlorophenol, and many other organics are negatively associated with BMD/BMC levels at specific sites in the human body [28,29,30]. The safety of urban centralized water supply largely relies on water disinfection as it kills pathogens and prevents waterborne infectious diseases [31]. However, water Disinfection Byproducts (DBPs) mostly contain certain VOCs. including chloroform, bromine, dibromochloromethane, and dichlorobromomethane, with chloroform presence being exceptionally high in these DBPs [32]. A survey specifically focused on chloroform was conducted in China to evaluate the health risks associated with municipal water supply. It analyzed the distribution pattern and seasonal chloroform variation characteristics in the municipal water supply in Xi'an and the average daily chloroform exposure dose. According to the results, the average daily exposure dose of chloroform in the Xi'an municipal water supply was 7.39\*10^-4 mg/(kg\*d), with drinking water consumption as the leading source for the non-carcinogenic risk of chloroform [33]. Another survey found that the carcinogenic risk of ten contaminants in city drinking water, including chloroform, exceeded the acceptable level [34]. All these studies indicate that chloroform could potentially harm human health, but no conclusive study has proven the dangers of chloroform exposure to public safety. Although some studies have associated chloroform co-exposure with bone health indicators [15], no link with

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

BMD has been reported. In our study, we hypothesize that there could be a connection between blood chloroform and BMD/BMC. After adjusting for confounders, we discovered a negative correlation between BMD/BMC and blood chloroform in L3 BMC and L4 BMD/BMC. Our analysis revealed a negative association between chloroform and femoral neck BMD in participants aged 65-80 years and Non-Hispanic White subjects, as well as Ward's triangle BMD in women and Non-Hispanic White subjects. For BMC, a negative correlation was found between blood chloroform and femoral neck BMC, Non-Hispanic White and Other Race-Including Multi-Racial subjects femoral neck BMC, female Ward's triangular BMC, Ward's Triangular BMC of female Non-Hispanic White and 65-80 years old subjects, Female L4 and Non-Hispanic White Subjects BMC, and L4 BMC of 45-65 years and 65-80 years old subjects. Multiple linear regression analysis and analysis within the Asian group revealed the relationship between blood chloroform and BMD/BMC in most areas of the femur and spine before adjusting for confounding factors. However, after adjusting for confounding variables, it was discovered that the correlation between blood chloroform and femoral BMD/BMC was not as strong. This finding implies that the relationship between blood chloroform and femoral BMD/BMC is largely influenced by age, gender, and race. On the one hand, this phenomenon may be attributed to femur and lumbar spine structures, which theoretically have the most substantial BMD changes in postmenopausal women with a higher proportion of cancellous bone [35, 36, 37, and 38]. On the other hand, it could be attributed to the sample population's old age (48.8  $\pm$ 

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

16.8 years), where hormonal drugs used by some older individuals exert a greater influence on femoral BMD/BMC than on lumbar spine BMD/BMC, making blood chloroform less likely to be associated with femoral BMD/BMC [39]. Furthermore, after adjusting for relevant covariates, stratified analysis by age, sex, and race revealed that chloroform concentration was negatively correlated with BMC at most sites. Blood chloroform concentration at L4 was significantly negatively correlated with BMC in women in the subgroup analysis. Contrastingly, no correlation between chloroform concentration and femoral or spinal BMC was observed in men, implying that blood chloroform levels may have some predictive value for bone mass in women. This phenomenon may be attributed to the sample population's older age ( $48.8 \pm 16.8$  years) and the substantial decline in sex hormone levels in postmenopausal women resulting in lower femoral BMD quantity. Men, on the other hand, showed no such specific changes. We hypothesized that the varying sex hormone levels might influence the femoral neck, Ward's triangle, or L4 BMC differently. Furthermore, the association between blood chloroform and femoral and spinal BMC was closer than that of BMD, which may be explained by the significant variations in the bone area resulting from individual differences. Both BMD and BMC have been shown by studies to be significant osteoporosis indicators and to play a critical role in osteoporotic fracture development [40]. Our study revealed a negative correlation between blood chloroform in some spine regions and BMD/BMC. Chloroform is used as a solvent to soften material during endodontic treatment, and case studies revealed that during the patients' endodontic retreatment

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

visit, chloroform was extruded through the perforation into the periodontal ligament space, resulting in necrosis of the tooth-supporting bone [41]. Our findings on the negative effect of chloroform on bone loss are consistent with another research which discovered that organochlorine contaminants-exposure could impact fertility, the menstrual cycle, and other aspects of the human reproductive system [42,43]. In a pharmaceutical company, female personnel exposed to a mixture of organic solvents (including chloroform) exhibited higher Thyroid-Stimulating Hormone (TSH) levels than the non-exposed group, with a significant correlation between chloroform and TSH levels [44]. According to some clinical studies, a positive correlation exists between TSH and femoral and spinal BMD in early postmenopausal women [45]. Consequently, we speculate that chloroform may have a positive association with BMD/BMC mediated by hormones in vivo, and this hypothesis is supported by the "V"shaped correlation between chloroform, and BMD/BMC discovered in our study (Fig2-3). Additionally, we hope to find the link between chloroform and bone metabolism through preliminary data analysis and further basic research. In this regard, our group has already started collecting environmental exposure samples and establishing a sample bank. (Fig2-3:Restricted cubic spline plots between chloroform and femoral neck BMC and chloroform and L4 BMC) With this cross-sectional research, we plan to further explore the effect of chloroform exposure on BMD/BMC. Herein, we used raw data on blood chloroform and femoral and spinal BMD/BMC from adults selected from NHANES in 2009-2010, 2013-2014, and 2017-2020 to perform a Restricted Cubic Splines (RCS) analysis of the

relationship between chloroform and BMD/BMC. The non-linear connection between blood chloroform and spinal BMD/BMC revealed a "V" shaped correlation and a statistically significant association between chloroform levels within the 0-0.02 ng/ml range and spinal BMD/BMC (Figure2-3). According to the literature review in some studies, chloroform harms BMD/BMC. Contrastingly, some studies suggest that chloroform may have a positive association with BMD/BMC. However, no specific reference in the literature demonstrates a clear connection between chloroform and BMD/BMC; thus, more research is required to determine the optimal level of chloroform exposure in relation to BMD/BMC levels. The above findings imply that exposure to VOCs such as chloroform remains a major public health concern. Disinfection byproducts are ubiquitous, and people (particularly older adults) with prolonged exposure to the chloroform from these products must be especially aware of their long-term risks.

### Limitation

Our study had several limitations. First, the data used in this investigation was obtained from NHANES, and therefore it was difficult to establish the exact timing between chloroform exposure and changes in BMD. Consequently, we could only develop correlations but not causality at this point. More research through prospective studies is therefore required to investigate this further. Second, our data on subjects were primarily from a single time point, making it difficult to determine the association between chloroform and BMD/BMC over time, potentially leading to bias in classifying specific populations. Third, some data were from self-reported

questionnaires, which may have resulted in recall or misclassification bias. Fourth, missing whole-body skeletal BMD/BMC data impeded a comprehensive examination of the chloroform and BMD/BMC correlation. Finally, the residual confounding problem persisted despite employing multivariate adjustment techniques. We are developing a cohort of VOC exposure (including chloroform) in our city and expect that more convincing evidence elucidating the link between chloroform and BMD/BMC will soon be available.

# **Conclusion**

After adjustment for confounders, we established a "V" shaped correlation between blood chloroform and femoral spine BMD/ BMC, with a negative correlation at 0-0.02 ng/ml (p<0.05), especially for L4 BMC. Our research provides epidemiological evidence for further investigation into the correlation between chloroform and BMD/ BMC.

# Acknowledgements

This thesis would not have been possible without the consistent and valuable reference materials that I received from my supervisor whose insightful guidance and enthusiastic encouragement in the course of my shaping this thesis definitely gains my deepest gratitude.

### References

Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop Relat Res. 2000
 Mar;(372):139-50.10. doi:1097/00003086-200003000-00016

- 362 2. Farrah Z, Jawad AS. Optimising the management of osteoporosis. Clinical
- 363 medicine (London, England). 2020 Sep;20(5): e196-e201. doi:
- 364 10.7861/clinmed.2020-0131
- 365 3. Zhang R, Huang Q, Su G, Wei M, Cui Y, Zhou H, Song W, Di D, Liu J, Wang Q.
- Association between multiple vitamins and bone mineral density: a cross-sectional
- and population-based research in the NHANES from 2005 to 2006. Population-
- based research in the NHANES from 2005 to 2006. BMC Musculoskelet Disord.
- 369 2023 Feb 10;24(1):113. doi: 10.1186/s12891-023-06202-6
- 4. Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The
- epidemiology of osteoporosis. Br Med Bull. 2020 May 15;133(1):105-117.
- 372 doi:10.1093/bmb/ldaa005
- 5. Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley
- JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in Bone Density
- and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone
- 376 Miner Res. 2019 Apr;34(4):632-642. doi:10.1002/jbmr.3641
- 6. Levin VA, Jiang X, Kagan R. Estrogen Therapy for osteoporosis in the modern
- era. Osteoporos Int. 2018;29(5):1049-1055. doi: 10.1007/s00198-018-4414-z
- 7. Chen LR, Hou PH, Chen KH. Nutritional support and physical modalities for
- people with osteoporosis: current opinion. Nutrients. 2019;11(12): 15. doi:
- 381 10.3390/nu11122848
- 8. Li Adela Jing, Pal Vineet Kumar, and Kannan Kurunthachalam. A review of
- environmental occurrence, toxicity, biotransformation and biomonitoring of

- volatile organic compounds." 3.(2021):91-116.
- 9. McGraw KE, Riggs DW, Rai S, Navas-Acien A, Xie Z, Lorkiewicz P, et al.
- Exposure to volatile organic compounds acrolein, 1,3-butanadiene, and
- crotonaldehyde is associated with vascular dysfunction, environ res. (2021)
- 388 196:110903. doi:10.1016/j. envres.2021.110903
- 10. Wei C, Chen Y, Yang Y, Ni D, Huang Y, Wang M, Yang X, Chen Z. Assessing
- Volatile Organic Compounds Exposure and Prostate-specific Antigen: National
- Health and Nutrition Examination Survey, 2001-2010. Front Public Health. 2022
- Jul 29; 10: 957069. doi:10.3389/fpubh.2022.957069
- 393 11. National Toxicology Program. NTP toxicology and carcinogenesis studies of
- methyl bromide (CAS: 74-83-9) in B6C3F1 mice (inhalation studies). Natl Toxicol
- 395 Program Tech Rep Ser. 1992 Mar; 385: 1-212.
- 396 12. Smith JT, Schneider AD, Katchko KM, Yun C, Hsu EL. Environmental factors
- impacting bone-relevant chemokines. Front Endocrinol (Lausanne). 2017 Feb 14;
- 398 8: 22. doi: 10.3389/fendo.2017.00022
- 399 13. Lehmann I, Roder-Stolinski C, Nieber K, Fischader G. In vitro models for the
- assessment of inflammatory and immuno-modulatory effects of the volatile
- organic compound chlorobenzene. Exp Toxicol Pathol (2008) 60(2–3):185–93. doi:
- 402 10.1016/j.etp.2008.01.009
- 403 14. Fischader G, Roder-Stolinski C, Wichmann G, Nieber K, Lehmann I. Release of
- 404 MCP-1 and IL-8 from lung epithelial cells exposed to volatile organic compounds.
- Toxicol In Vitro (2008) 22(2):359–66. doi: 10.1016/j.tiv.2007.09.015

- 406 15. Zhou HL, Su GH, Zhang RY, Di DS, Wang Q. Association of volatile organic
- compounds co-exposure with bone health indicators and potential mediators.
- 408 Chemosphere. 2022 Dec;308(Pt 1):136208. doi:
- 409 10.1016/j.chemosphere.2022.136208
- 16. Batterman S, Su FC, Li S, Mukherjee B, Jia C; HEI Health Review Committee.
- Personal exposure to mixtures of volatile organic compounds: modeling and res
- health eff Inst. 2014 Jun;(181):3-63.
- 17. Toxicity of Chloroform. Prescrire Int. 1998 Oct;7(37):149.
- 18. Cui Y, Zhou HL, Wei MH, Song WJ, Di DS, Zhang RY, et al. Multiple vitamin
- 415 co-exposure and mortality risk: a prospective research. Clin Nutr. 2022; 41(2): 337
- 416 -347. doi: 10.1016/j.clnu.2021.12.010
- 19. Lee S, Ko K, Shin S, Park HS, Hong N, Rhee Y. Adipopenia is associated with
- osteoporosis in community-dwelling non-underweight adults independent of
- sarcopenia. Arch Osteoporos. 2023 Mar 22;18(1): 44. doi:10.1007/s11657-023-
- 420 01233-x
- 20. Song S, Guo Y, Yang Y, Fu D. Advances in pathogenesis and therapeutic strategies
- for osteoporosis. *Pharmacol Ther*. (2022) 237:108168. doi:
- 423 10.1016/j.pharmthera.2022.108168
- 424 21. Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, et al.
- Osteoporosis in the European Union: medical management, epidemiology and
- economic burden. A report prepared in collaboration with the international
- osteoporosis foundation (IOF) and the European Federation of Pharmaceutical

Associations (EFPIA). Arch Osteoporos. (2013) 8:136. doi: 428 Industry 10.1007/s11657-013-0136-1 429 22. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et 430 al. The global prevalence of osteoporosis in the world: a comprehensive systematic 431 review and meta-analysis. J Orthop Surg Res. 2021 Oct 17;16(1):609. doi: 432 10.1186/s13018-021-02772-0 433 23. Konkle SL, Zierold KM, Taylor KC, Riggs DW, Bhatnagar A. National secular 434 trends in ambient air volatile organic compound levels and biomarkers of exposure 435 in the United States. Environ Res. (2020) 182:108991. doi:10.1016/j.envres. 436 2019.108991 437 24. Jain RB. Detection Rates, Trends in and factors affecting observed levels of 438 439 selected volatile organic compounds in blood among us adolescents and adults. Environ Toxicol Pharmacol.(2017) 56:21-8.doi:10.1016/j.etap.2017.08.031 440 25. Jain RB. Distributions of selected urinary metabolites of volatile organic 441 compounds by age, gender, race/ethnicity, and smoking status in a representative 442 sample of US adults. Environ Toxicol Pharmacol. (2015) 40: 471-9. 443 doi:10.1016/j.etap.2015.07.018 444 26. Liu B, Jia C. Effects of exposure to mixed volatile organic compounds on the 445 neurobehavioral test performance in a cross-sectional research of US adults. Int J 446 Environ Health Res. (2015) 25: 349-63. doi:10.1080/09603123.2014.945514 447 27. Su FC, Jia C, Batterman S. Extreme value analyses of VOC exposures and risks: a 448

449

comparison of riopa and NHANES datasets. atmospheric environ. (2012) 62:97.

- 450 106. doi: 10.1016/j.atmosenv. 2012.06.038
- 451 28. Yan Z, Xiong X, Tao J, Wang S. Association of bone mineral density with
- 452 trichlorophenol: a population-based research. BMC musculoskelet disord. 2023
- 453 Mar 17. 24(1): 202. doi:10.1186/s12891-023-06323-y
- 454 29. Kirk AB, DeStefano A, Martin A, Kirk KC, Martin CF. A new interpretation of
- relative importance on an analysis of per and polyfluorinated alkyl substances
- 456 (PFAS) exposures on bone mineral density. Int J Environ Res Public Health. 2023
- 457 Mar 3; 20 (5): 4539. doi:10.3390/ijerph20054539
- 458 30. Yang R, Chen Z, Hu Y. Associations of urinary polycyclic aromatic hydrocarbons
- with bone mineral density at specific body sites in U.S. Adults, National Health
- and Nutrition Examination Survey 2001 to 2004. Endocr Pract. 2022 Sep; 28(9):
- 461 867-874.10.1016/j.eprac.2022.06.008
- 462 31. Yang KD. Environmental hygiene (M). Beijing: people's medical publishing house,
- 463 2017.
- 32. Xu H, Cai J. Determination and risk assessment of disinfection by- products in
- drinking water of S city(J). Water & Wastewater Engineering, 2020,56(9):37-40.
- 33. Zhao GP, Zou KT, Xu O, Liu RX, Luo XH, Guan R. Distribution characteristics
- and multi pathways health risk assessment of trichloromethane in municipal water
- of Xi'an.Modern Preventive Medicine(J). 2023,50(4):611-617.
- 469 34. Han JY, Ye BX, Zhang L. Health Risk Assessment of 10 pollutants in a city's
- drinking water. Journal of environmental hygiene Jun(J). 2019,9(3):203-209.
- 471 35. Wang C, Zhu Y, Long H, Ou M, Zhao S. Connection between blood manganese

and bone mineral density and bone mineral content in adults: a population-based 472 cross-sectional research. PLoS One. 2022 Oct 21; 17(10): e0276551. 473 doi:10.1371/journal.pone.0276551 474 36. Mosekilde L, Danielsen CC, Gasser J. The effect on vertebral bone mass and 475 strength of long term treatment with antiresorptive agents (estrogen and calcitonin), 476 human parathyroid hormone-(1-38), and combination therapy, assessed in aged 477 ovariectomized Endocrinology. 1994 rats. May;134(5):2126-34. doi: 478 10.1210/endo.134.5.8156913. 479 37. Liu J, Wang W, Tong QJ, et al. A comparative research of dual-energy X-ray bone 480 densitometry (DXA) and A comparative research of bone density measurement by dual-energy X-ray bone densitometry (DXA) and quantitative CT (QCT)(J). 482 483 Journal of Clinical Radiology. 2007, 26(5): 504-507. 38. Yamauchi H, Kushida K, Yamazaki K, et al. Assessment of spine bone mineral 484 density in ovariectomized rats using DXA(J). J Bone Miner Res, 1995, 10(7): 485 486 1033-1036. doi: 10.1002/jbmr.5650100707 39. Yin X, Zhao S, Xiang N, Chen J, Xu J, Zhang Y. Efficacy of Bushen Jiangu therapy 487 in the treatment of glucocorticoid-induced osteoporosis: A systematic review and 488 meta-analysis of randomized controlled trials. Medicine (Baltimore). 2023 Mar 489 17;102(11): e33278. doi: 10.1097/MD.0000000000033278 490 40. Deng HW, Xu FH, Davies KM, Heaney R, Recker RR. Differences in Bone Mineral Density, Bone Mineral Content, and Bone Areal Size in Fracturing and 492

481

491

493

Non-fracturing Women, and Their Interconnections at the Spine and Hip.

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514


515


Fracturing Women, and Their Interconnections at the Spine and Hip. Journal of bone and mineral metabolism. 2002; 20(6): 358-66.doi:10.1007/s007740200052 41. Mohammadzadeh Akhlaghi N, Baradaran Mohajeri L, Fazlyab M. Tissue Necrosis due to Chloroform: a Case Report. Iran Endod J. 2013 Fall;8(4):208-9. 42. Bonde JP, Toft G, Rylander L, Rignell-Hydbom A, Giwercman A, Spano M, Manicardi GC, Bizzaro D, Ludwicki JK, Zvyezday V, Bonefeld-Jørgensen EC, Pedersen HS, Jönsson BA, Thulstrup AM; INUENDO. Fertility and markers of male reproductive function in Inuit and European populations spanning large contrasts in blood levels of persistent organochlorines. Environ Health Perspect. 2008 Mar; 116(3):269-77. doi: 10.1289/ehp.10700 43. Figa-Talamanca I. Occupational risk factors and reproductive health of women. Occup Med (Lond) 2006; 56: 521–531. doi: 10.1093/occmed/kgl114 44. Hassani S, Namvar M, Ghoreishvandi M, Attarchi M, Golabadi M, Seyedmehdi SM, Khodarahmian M. Menstrual disturbances and hormonal changes in women workers exposed to a mixture of organic solvents in a pharmaceutical company. Med J Islam Repub Iran. 2014 Dec 27; 28:156. 45. Begić A, Begić A, Arnautović-Halimić A. Influence of thyroid hormones on bone density. Med Glas (Zenica). 2020 Feb 1;17(1):35-40. doi: 10.17392/1056-20 **Supporting information** S1 Table Related demographic characteristics of participants included in NHANES from 2009 to 2010 and 2013 to 2014 and 2017-2020. Means with standard deviation (SD) were used for continuous characteristic variables and

categorical variables were expressed as frequencies. Differences in categorical variables between exposed groups were analyzed by Kruskal Wallis test or Mann Whitney test. Spearman correlation analysis was used to analyze the differences of continuous variables between groups.


(EXCEL)

S2 Table Blood chloroform and area, BMC, and BMD based on chloroform tristimulus. Data are expressed as means (standard deviation, SD). BMC, bone mineral content, BMD, bone mineral density, Area (cm2), BMC (g), BMD (g/cm2). (EXCEL)





Figure



Figure